Breast Cancer Expert Nancy Davidson Elected ASCO President for 2007-2008

Publication
Article
OncologyONCOLOGY Vol 20 No 7
Volume 20
Issue 7

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

Nancy E. Davidson, MD, a medical oncologist who has specialized in breast cancer for more than 20 years, has been elected to become president of the American Society of Clinical Oncology (ASCO) for a 1-year term beginning in June 2007. She took office as president-elect this month, during ASCO's 42nd annual meeting in Atlanta.

In addition, Bruce J. Roth, MD, professor of medicine/urologic surgery at Vanderbilt-Ingram Cancer Center, was elected secretary-treasurer for the 2006-2009 term. Five new members were elected to the ASCO board of directors (Howard A. Burris III, MD, Waun Ki Hong, MD, FACP, DMSC, Thomas Marsland, MD, Gregory H. Reaman, MD, and Martine J. Piccart-Gebhart, MD, PHD) and two new members to the ASCO nominating committee (Edith Perez, MD, and Eric P. Winer, MD), all for 3‑year terms beginning in June 2006.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.